Navigation Links
ESA and EC take major step forward in GMES
Date:12/19/2007

ESA and the European Commission have signed a 48 million grant that will allow the space agency to ensure the coordinated and timely supply of satellite-based Earth Observation data for the preoperational phase of GMES from 2008 to 2010. The signing of the grant marks the first real cooperation between the two in the GMES framework.

The GMES (Global Monitoring for Environment and Security) programme is a European Union-led initiative in partnership with ESA to combine ground- and space-based observations to develop an integrated environmental monitoring capability.

ESAs role within GMES is to coordinate and implement the dedicated GMES Space Component, which involves developing the five Sentinel satellites, and Ground Segment and to coordinate data access to the Sentinels and to other missions mainly from ESA Member States which contribute to fulfilling of the GMES requirements.

Following the signing of the GMES Space Component Data Access (GSC-DA) grant, European Commission (EC) Vice-President Gnter Verheugen, who is responsible for enterprise and industry policy, said: "Globally, changes in environmental conditions lead to increased risks for economical, social and political stability, which further affect European security."

Coordinated, comprehensive and sustained global monitoring of the Earth system is one of the key factors to respond to this challenge. GMES is the European solution for the needs of citizens in Europe to access reliable information on the status of their environment."

Dr Volker Liebig, Director of ESAs Earth Observation Programme, signed the agreement on behalf of ESA. "The data access grant is the first step of a wider GMES cooperation with the EC, using ESA's 30 years of experience in collecting and distributing necessary Earth Observation data to users," Liebig said.

The data access grant will support the GMES services, which today include three fast-track services focusing on lan
'/>"/>

Contact: Simonetta Cheli
simonetta.cheli@esa.int
39-069-418-0350
European Space Agency
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... known as marijuana is broadly believed to ... (MGH) investigators found that 40 percent of cannabis-using ... reported experiencing symptoms of withdrawal, which are considered ... reporting withdrawal were more likely to meet criteria ... although the presence or absence of withdrawal did ...
(Date:9/1/2014)... Building on the success of the ... and Breathing Academy (ASBA) has officially announced its ... Professionals. The event will be taking place at the ... 11th. This years’ event promises to be yet another ... , In recent years, Pro Player Health Alliance ...
(Date:9/1/2014)... HealthDay Reporter SATURDAY, Aug. 30, ... experimental drug was more effective than standard treatment at ... According to the study authors, the trial was stopped ... drug, dubbed LCZ696. In the trial, 26.5 ... either died or were hospitalized due to heart failure, ...
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... specially-fitted room in a hospital for performing surgical operations. ... such as operating tables, surgical booms, operating room lights, ... rooms. According to a report by Transparency Market Research, ... market is expected to reach USD 4.5 billion by ...
(Date:9/1/2014)... 1 September 2014: Daily fruit consumption cuts the risk ... to research presented at ESC Congress today by Dr ... seven year follow-up study of nearly 0.5 million people ... fruit people ate, the more their risk of CVD ... disease (IHD) and stroke, is the leading cause of ...
Breaking Medicine News(10 mins):Health News:Cannabis withdrawal symptoms common among adolescents treated for substance use disorder 2Health News:Cannabis withdrawal symptoms common among adolescents treated for substance use disorder 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 2Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 4Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... DARIEN, Ill., June 17 Healthation CEO Scott ... Vice President of,Business Development today. Mr. Hebert was ... experience in sales of complex solutions in the ... the sales and,marketing organization and growing market share ...
... PartsSource, the nation,s leading,supplier of replacement medical ... straight "World Class Customer Service" award for Northern,Ohio. ... Promise and,its ability to consistently meet or exceed ... by Smart Business magazine, which further,honored PartsSource,s President ...
... NORTH HOLLYWOOD, Calif., June 17 IPC The,Hospitalist ... national hospitalist,physician group practice, today announced that it ... and Exchange Commission in connection,with a proposed offering ... shares to be registered include 3,889,769 shares owned ...
... extract reduces plaque formation and resulting cognitive impairment in ... The study appears in the June 18 issue of ... study author Giulio Pasinetti, MD, PhD, of Mount Sinai ... seed extract prevents amyloid beta accumulation in cells, suggesting ...
... researchers at Washington University School of Medicine in St. ... the risk of metabolic syndrome, a group of factors ... found appeared to protect against the condition. , People ... following symptoms: abdominal obesity, high blood triglyceride levels, lower ...
... and stress-reduction spur healthy alterations in DNA, study finds, ... not fully control your destiny when it comes to ... with prostate cancer. , New research suggests that stringent ... can change the expression of hundreds of genes. ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 2Health News:IPC The Hospitalist Company, Inc. Files Registration Statement for Proposed Offering 3Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 2Health News:Study indicates grape seed extract may reduce cognitive decline associated with Alzheimer's disease 3Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 2Health News:Gene variants linked to metabolic syndrome and HDL cholesterol levels 3Health News:Lifestyle Changes Affect Cancer Genes 2Health News:Lifestyle Changes Affect Cancer Genes 3
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 29, 2014 Diseases largely eradicated in ... are returning. Measles was declared eliminated in 2000, yet ... of August 15—the highest incidence in 20 years. In ... declared whooping cough a problem of "epidemic proportions." ... and dying from these preventable diseases—in part because some ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFBI), a ... Exchange, proceeds with the development of its,third drug ... is currently,in clinical trials and CF102, which is ... the EUALR annual congress of,rheumatology in-vitro and in ...
... of SLE,disease at 52 Weeks and demonstrated ... ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- ... of Phase 2,trial data demonstrating that LymphoStat-B(R) ... was well tolerated and improved quality of ...
Cached Medicine Technology:Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8